The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Blood

• Publication date

  2008-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2007-08-109090PMID 17957027
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.

  2007cited by this paper
• The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence

  2007cited by this paper
• The incidence and clinical significance of nucleophosmin mutations in childhood AML.

  2007cited by this paper
• Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.

  2007cited by this paper
• FLT3 mutations: biology and treatment.

  2006cited by this paper
• DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412

  2006cited by this paper
• Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

  2006cited by this paper
• Clinical implications of FLT3 mutations in pediatric AML.

  2006cited by this paper
• Nucleophosmin and cancer

  2006cited by this paper
• More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML).

  2006cited by this paper
• Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

  2006cited by this paper
• Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.

  2006cited by this paper
• The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.

  2006cited by this paper
• The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients

  2006influential reference
• Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

  2005cited by this paper
• No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

  2005cited by this paper
• Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias.

  2005cited by this paper
• Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

  2005cited by this paper
• Acquired Isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations

  2005cited by this paper
• Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

  2005cited by this paper
• A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

  2004cited by this paper
• Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.

  2004cited by this paper
• FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia

  2004cited by this paper
• The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.

  2004cited by this paper
• The role of FLT3 in haematopoietic malignancies

  2003influential reference
• Flt3 mutations and leukaemia

  2003influential reference
• Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

  2002cited by this paper
• The roles of FLT3 in hematopoiesis and leukemia.

  2002cited by this paper
• Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

  2002cited by this paper
• Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.

  2002cited by this paper
• Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse.

  2002cited by this paper
• Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

  2001cited by this paper
• Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

  2000cited by this paper
• Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

  2000influential reference
• Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

  1996cited by this paper
• Quantification of X-chromosome inactivation patterns in haematological samples using the DNA PCR-based HUMARA assay.

  1996cited by this paper

• Integrating FLT3-ITD molecular features with clinical risk factors improves risk stratification in acute myeloid leukemia

  2026cites this paper
• NPM1 Measurable Residual Disease: A Narrative Review

  2025cites this paper
• Differences in prognostic value of FLT3 and NPM1 mutations in older and younger patient populations with acute myeloid leukemia

  2025cites this paper
• A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia

  2025cites this paper
• Internal tandem duplications of FLT3 containing exogenous sequences are associated with poor clinical outcomes in acute myeloid leukemia

  2025cites this paper
• Frontline Therapy of AML in the Fit and Younger Population—Incorporating Molecularly Targeted Agents

  2025cites this paper
• A Case of Acute Myeloid Leukemia with an FMS-like Tyrosine Kinase 3-tyrosine Kinase Domain Mutation Developing Gilteritinib-induced Differentiation Syndrome.

  2025cites this paper
• Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells

  2025cites this paper
• Real-world data on adult AML with FLT3-ITD mutation from the Thai acute leukemia working group

  2025cites this paper
• Antitumor activity of gilteritinib, an inhibitor of AXL, in human solid tumors

  2025cites this paper
• Targeted therapy of newly diagnosed FLT3-mutated acute myeloid leukemia. A single-center ambispective cohort study

  2025cites this paper
• Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study

  2025cites this paper
• Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection

  2025cites this paper
• Determination of FLT3 mutations and minimal residual deasease monitoring in FLT3-positive acute myeloid leukemia

  2025cites this paper
• Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia

  2025cites this paper
• Peposertib suppresses generation of FLT3-internal tandem duplication formed by contralateral double nicks.

  2025cites this paper
• Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical Review

  2025cites this paper
• BAALC-expressing stem cell fractions: studies in patients with FLT3-mutated and juvenile myelomonocytic leukemias

  2025cites this paper
• Targeting leukemic stem cell dormancy in NPM1c/FLT3-ITD-driven acute myeloid leukemia

  2025cites this paper
• Prognostic covariates associated with outcomes in patients with NPM1-mutated acute myeloid leukemia

  2025cites this paper
• The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry

  2025cites this paper
• Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia

  2024cites this paper
• Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia

  2024cites this paper
• Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies

  2024cites this paper
• Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead

  2024cites this paper
• Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.

  2024cites this paper
• Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin

  2024cites this paper
• Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions

  2024cites this paper
• Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations

  2024cites this paper
• Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy

  2024cites this paper
• Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

  2024cites this paper
• BRCC36 associates with FLT3‐ITD to regulate its protein stability and intracellular signaling in acute myeloid leukemia

  2024cites this paper
• Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine

  2024cites this paper
• Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center

  2024cites this paper
• Treatment Patterns and FLT3 Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational Study

  2024cites this paper
• Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML

  2024cites this paper
• Advancements and Challenges in the Treatment of AML.

  2024cites this paper
• CLONAL DYNAMICS AND RELAPSE RISK REVEALED BY HIGH SENSITIVITY FLT3-ITD DETECTION IN ACUTE MYELOID LEUKEMIA.

  2024cites this paper
• High DOCK1 expression identifies a distinct prognostic subgroup of pediatric acute myeloid leukemia: Results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML‐05 trial

  2024cites this paper
• Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia

  2024cites this paper
• Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia

  2024cites this paper
• Outcomes of Patients with FLT3 Positive Acute Myeloid Leukaemia; an Experience from a Tertiary Care Hospital in Karachi, Pakistan

  2023cites this paper
• What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?

  2023cites this paper
• FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

  2023cites this paper
• A novel subclonal rearrangement of the STRN3::PDGFRB gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects

  2023influential citation
• Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth

  2023cites this paper
• Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

  2023cites this paper
• Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

  2023cites this paper
• Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients

  2023cites this paper
• Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia

  2023cites this paper
• How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?

  2023cites this paper
• Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

  2023cites this paper
• Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question

  2023cites this paper
• Prognostic relevance of NPM1, CEBPA, and FLT3 mutations in cytogenetically normal adult AML patients.

  2023cites this paper
• How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia

  2023influential citation
• The clinical impact of the molecular landscape of acute myeloid leukemia

  2023cites this paper
• Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation

  2023cites this paper
• Genomic Alterations, Gene Expression Profiles and Functional Enrichment of Normal-Karyotype Acute Myeloid Leukaemia Based on Targeted Next-Generation Sequencing

  2023cites this paper
• The expression level of ARF and p53 in AML patients, and their relation to patients' outcome

  2023cites this paper
• The function and regulation of CCAAT/enhancer binding protein ε

  2023cites this paper
• Genetic landscape of acute myeloid leukemias with leukocytosis

  2023cites this paper
• Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician.

  2023cites this paper
• The FLT3-ITD allelic ratio and NPM1 mutation do not impact outcomes in AML patients with FLT3-ITD after allo-HSCT: a retrospective propensity-score matching study.

  2023cites this paper
• Recent advances in targeted therapies in acute myeloid leukemia

  2023cites this paper
• Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia

  2023cites this paper
• Menin–MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers

  2023cites this paper
• Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth

  2023cites this paper
• Venetoclax in adult acute myeloid leukemia.

  2023cites this paper
• A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment

  2023cites this paper
• Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores

  2023cites this paper
• Network-based clustering unveils interconnected landscapes of genomic and clinical features across myeloid malignancies

  2023cites this paper
• Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia

  2023cites this paper
• The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus

  2023influential citation
• How I treat AML incorporating the updated classifications and guidelines

  2023cites this paper
• Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myeloid Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy.

  2022cites this paper
• Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study

  2022cites this paper
• Revealing molecular architecture of FLT3 internal tandem duplication: Development and clinical validation of a web‐based application to generate accurate nomenclature

  2022cites this paper
• Somatic mutation-associated risk index based on lncRNA expression for predicting prognosis in acute myeloid leukemia

  2022cites this paper
• Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications

  2022cites this paper
• FLT3-targeted treatment for acute myeloid leukemia

  2022cites this paper
• Mutation profile of the patients diagnosed with myeloid neoplasia tested with next generation sequencing and clinical implications

  2022cites this paper
• Association of FLT3-internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis

  2022cites this paper
• Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors

  2022influential citation
• Which FLT3 Inhibitor for Treatment of AML?

  2022cites this paper
• Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents

  2022cites this paper
• Hyperleukocytosis and leukostasis in acute and chronic leukemias

  2022cites this paper
• Single cell proteogenomic sequencing identifies a relapse‐fated AML subclone carrying FLT3‐ITD with CN‐LOH at chr13q

  2022cites this paper
• Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia

  2022cites this paper
• Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML

  2022cites this paper
• Assessing the impact of the 2017 European LeukemiaNet recommendations on FLT3 allelic ratio calculation and reporting in acute myeloid leukaemia

  2022cites this paper
• Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

  2022cites this paper
• The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms

  2022cites this paper
• Technical Validation and Clinical Utility of an NGS Targeted Panel to Improve Molecular Characterization of Pediatric Acute Leukemia

  2022cites this paper
• Evaluation of morphological, clinical, and prognostic significance of nucleophosmin gene mutation in de novo acute myeloid leukemia: A retrospective study

  2022cites this paper
• FLT3-ITD Measurable Residual Disease Monitoring in Acute Myeloid Leukemia Using Next-Generation Sequencing

  2022cites this paper
• Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios

  2022cites this paper
• Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

  2022cites this paper
• Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches

  2022cites this paper
• Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML

  2022cites this paper
• Chromosomal breaks at the origin of small tandem DNA duplications

  2022cites this paper